Each claim is a single, precisely-scoped question. A study does not get a blanket "pro" or "anti" label; instead it contributes evidence to the specific claims it speaks to. Every claim argues both the mainstream and the skeptic case, and carries a clearly-labelled bottom line.
The bars below show how the evidence divides, with each study weighted by its strength (an ordinal display scale, not a probability). Raw study counts are shown alongside.
Muscle aches are the most common reason people stop statins, and the symptoms are real. The contested question is the cause. When patients are blinded - not knowing whether they are taking the statin or a placebo - the aches show up almost as often on placebo, which means much of the symptom burden is driven by expectation (the nocebo effect) rather than the drug. This does not deny that a minority have genuine statin-induced muscle effects; it reframes how often the drug is truly the culprit.
This is the crux of the site owner's own situation: low-carb eating tends to improve most metabolic markers while often pushing LDL up. The trial evidence fairly consistently shows better weight, triglycerides, HDL and blood-sugar control on low-carb, but it is not clearly superior to other healthy diets for weight, the LDL rise is real, and there are no long-term hard-outcome trials, so the net cardiovascular effect is genuinely unsettled.
Reducing heart attacks is not the same as living longer. The strongest evidence that statins extend life comes from secondary prevention and high-risk trials such as 4S, where total mortality fell. In low-risk primary prevention the all-cause mortality signal is weaker and disputed, which is why this claim is scoped by risk level rather than stated as a blanket fact.
This is one of the few statin harms that is well quantified and broadly accepted across both camps. Pooled trial data show a small but real increase in new diabetes diagnoses on statins, concentrated in people who already have risk factors for diabetes. The dispute is not whether it happens, but how to weigh it against cardiovascular benefit.
For people who have already had a heart attack (secondary prevention), statin benefit is widely accepted. The genuine debate is about primary prevention in people at low baseline risk: the relative risk reduction is real but the absolute benefit can be small, and how meaningful that is - against cost, side effects, and over many years - is contested.
A CAC scan is a quick CT that counts calcified plaque already in your coronary arteries. Unlike a cholesterol number, it measures disease that has actually formed. Higher scores track strongly with future heart attacks, and a score of zero marks a group whose near-term risk is low - which is why it is central to the skeptic argument that a high LDL with a zero calcium score may not warrant treatment. The main caveats: a zero score is reassuring, not a permanent pass, and CAC does not see soft (non-calcified) plaque.
The Mediterranean diet is the dietary pattern with the best randomized-trial support for reducing heart events, mainly from the PREDIMED trial. The evidence leans positive, but it comes with real caveats: PREDIMED had to be withdrawn and republished after randomization problems, the absolute benefit was modest and largely driven by stroke, and the trial received food-industry donations of the very foods it tested.
For decades guidelines capped dietary cholesterol; then many dropped the cap, arguing it has little effect on blood cholesterol for most people. The best recent observational data find a modest dose-response link between dietary cholesterol and cardiovascular events, but it is observational, the egg-specific signal disappears once you account for the cholesterol the eggs contain, and individual responses to dietary cholesterol vary widely.
This is the original "diet-heart" question and one of the most contested in nutrition. Read it carefully: this claim is about whether saturated fat intake *by itself* raises risk, which is a different question from whether *replacing* saturated fat with polyunsaturated fat reduces events (the latter has better trial support and is treated as a distinct question in the evidence below). The honest picture is conditional: observational data find saturated fat intake itself is not clearly tied to events, while replacement trials show benefit that depends on the replacement nutrient - so what you swap it for matters more than the saturated fat alone.
Mainstream science treats LDL as a genuine cause of artery disease, supported by genetics, drug trials, and large population studies that point the same way. A vocal minority argues the causal claim is overstated, especially in older and metabolically healthy people. The honest reading: LDL is very likely a real causal contributor, but how much it matters for any one person depends heavily on their baseline risk and metabolic context.
If statins worked through some effect other than LDL lowering, then drugs that lower LDL by completely different mechanisms should not help. They do. Ezetimibe and PCSK9 inhibitors lower LDL through different pathways and both reduced events in large trials. This is one of the strongest arguments that LDL lowering itself is doing the work - though the per-trial mortality picture is more mixed.
The same LDL number may carry different risk depending on the body it sits in. Inflammation and insulin resistance appear to amplify risk, while a healthy metabolic profile (low triglycerides, high HDL, no plaque) appears to blunt it. How much context changes the picture is debated, but that it matters is increasingly accepted.
Standard LDL-C measures the cholesterol carried inside LDL particles, not how many particles there are. When those two disagree (discordance), risk tends to track the particle count (ApoB), not the cholesterol number. This view is increasingly accepted - even by people on opposite sides of the LDL-causality debate - though guidelines still lead with LDL-C for cost and habit.
Lp(a) is a particle most people never get tested for, yet the genetic evidence that it causes heart disease is unusually strong - arguably cleaner than for LDL itself, because Lp(a) levels are set mostly by your genes from birth. This makes it a near-ideal natural experiment. The main open questions are not whether it is causal, but how much it adds on top of LDL and whether lowering it helps.
Some lean, fit, low-carb dieters see their LDL soar while keeping high HDL and low triglycerides - the opposite of the usual high-risk pattern. The open question is whether this particular very-high-LDL state is dangerous. There is not yet long-term outcome data either way, so this is the most genuinely unsettled claim on the site.